March 1st 2018
The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.
September 3rd 2017
After a decade of little movement in the treatment of advanced hepatocellular carcinoma (HCC), there are promising developments on the horizon, according to recent study findings.
April 20th 2017
As the population of cancer survivors has grown, so has the risk that patients will develop— and succumb to—a second cancer.
March 1st 2017
Despite advances in the oncology field, venous thromboembolism remains a significant problem for patients with cancer.
December 2nd 2016
Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.
August 17th 2016
Although researchers have been exploring gene editing for more than 40 years, scientists say the CRISPR technology offers game-changing methods for anticancer research as well as a host of other applications.
May 24th 2016
The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.
January 29th 2016
Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.